Intrinsic Therapeutics closed a US $49MM round of financing, which will support global commercialization of the Barricaid Anular Closure Device.
Barricaid is designed to prevent reherniation following lumbar discectomy surgery to treat sciatic pain caused by a herniated disc. In 4Q16, the company filed a Premarket Application with FDA based on 2-year outcomes of 554 trial subjects with a high risk of reherniation, subsequent reoperation and rehospitalization. Barricaid is reported to be the first of its kind in a prospective randomized superiority trial involving patients who are at higher risk for revision discectomy to alleviate recurrent pain resulting from reherniation
The financing included a $28MM equity round co-led by New Enterprise Associates and Delos Capital, as well as a $21MM debt facility with investment firm CRG. Other investors include Greenspring Associates, Quadrille Capital and a corporate strategic.
Sources: Intrinsic Therapeutics, Inc.; ORTHOWORLD Inc.
Intrinsic Therapeutics closed a US $49MM round of financing, which will support global commercialization of the Barricaid Anular Closure Device.
Barricaid is designed to prevent reherniation following lumbar discectomy surgery to treat sciatic pain caused by a herniated disc. In 4Q16, the company filed a Premarket Application with FDA based on...
Intrinsic Therapeutics closed a US $49MM round of financing, which will support global commercialization of the Barricaid Anular Closure Device.
Barricaid is designed to prevent reherniation following lumbar discectomy surgery to treat sciatic pain caused by a herniated disc. In 4Q16, the company filed a Premarket Application with FDA based on 2-year outcomes of 554 trial subjects with a high risk of reherniation, subsequent reoperation and rehospitalization. Barricaid is reported to be the first of its kind in a prospective randomized superiority trial involving patients who are at higher risk for revision discectomy to alleviate recurrent pain resulting from reherniation
The financing included a $28MM equity round co-led by New Enterprise Associates and Delos Capital, as well as a $21MM debt facility with investment firm CRG. Other investors include Greenspring Associates, Quadrille Capital and a corporate strategic.
Sources: Intrinsic Therapeutics, Inc.; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.